Table 1.
Comparing cohorts A through C
| Cohort A, exclusively anthracycline-based (n=19) | Cohort B, taxane-based/others (n=50) | Cohort C, no chemotherapy (n=45) | Statistics, P-value | |
|---|---|---|---|---|
| Parameter | ||||
| Median age in years, range | 60 (44–73) | 49 (27–75) | 72 (36–87) | <0.001 |
| Size, pT (tumor stage) | 0.241 | |||
| pT1 | 7 (36.8%) | 17 (34.0%) | 16 (35.5%) | |
| pT2 | 9 (47.4%) | 28 (56.0%) | 20 (44.4%) | |
| pT3 | 2 (20.0%) | 5 (10.0%) | 3 (6.7%) | |
| pT4 | 1 (14.3%) | 0 (0%) | 6 (13.3%) | |
| Histological type | 0.017 | |||
| Invasive ductal | 16 (84.2%) | 45 (90.0%) | 32 (71.1%) | |
| Invasive lobular | 3 (15.8%) | 1 (2.0%) | 11 (24.4%) | |
| Other | 2 (4.4%) | 4 (8.0%) | 2 (33.3%) | |
| Pathologic nodal status (pN) | 0.001 | |||
| pN0 | 2 (42.2%) | 8 (16.0%) | 19 (42.2%) | |
| pN1 | 6 (13.3%) | 27 (54.0%) | 6 (13.3%) | |
| pN2 | 11 (24.4%) | 10 (20.0%) | 11 (24.4%) | |
| pN3 | 9 (20.0%) | 5 (10.0%) | 9 (20.0%) | |
| Pathologic grade | 0.619 | |||
| G1 | 0 (0%) | 4 (8.0%) | 5 (11.1%) | |
| G2 | 11 (57.9%) | 30 (60.0%) | 26 (57.8%) | |
| G3 | 8 (42.1%) | 16 (32.0%) | 14 (31.1%) | |
| Estrogen receptor status | 0.245 | |||
| Estrogen receptor positive | 13 (68.4%) | 36 (72.0%) | 38 (84.4%) | |
| Estrogen receptor negative | 6 (31.6%) | 14 (28.0%) | 7 (15.6%) | |
| Human epidermal growth factor receptor 2 status | <0.001 | |||
| Human epidermal growth factor receptor 2 negative | 18 (94.7%) | 30 (61.2%) | 41 (93.2%) | |
| Human epidermal growth factor receptor 2 positive | 1 (5.3%) | 19 (38.8%) | 3 (6.8%) | |
Notes: Cohort A, patients receiving exclusively anthracycline-based chemotherapy. Cohort B, patients receiving chemotherapy including agents other than anthracyclines (eg, taxane-based and others). Cohort C, patients receiving no chemotherapy.